TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05673018: Galleri® in the Medicare Population.

Sponsor: GRAIL, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 50000 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05673018 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05673018 Rescue Dossier →